Under the agreement, Archimedes Development Ltd is responsible for the development of the formulation to the end of phase I and Almac Discovery collaborate on the clinical development of the product.
The clinical trial, in spring 2010 in spring 2010, is the safety, bioavailability and pharmacokinetics of a single dose of intranasal Granisetron compared with oral and intravenous formulations. Dr Stephen Barr, Managing Director and President of Almac Discovery, said: ‘The commencement of this phase I study with intranasal Granisetron is an important milestone for Almac Discovery It underlines our commitment to improving the quality of life of patients receiving chemotherapy. ‘.The evidence there is is to support to the community has and the frantic campaign that being conducted by the tobacco industry, a further indication that it should work.
‘There is no wonder, in Australia that many Australians supporting neutral packaging such who is it. – ‘The Parliament has is a unique opportunity to verify the evidence and the support of public into revolutionary politics with high potential to further reduction of tobacco consumption in Australia, which remain is far of the nation to dictionary for huge avoidable cause of of cancer death.